The interleukin-6 promoter (-597/-572/-174)genotype does not affect interleukin-6 production in hemodialysis patients.

Kidney transplant recipients with the interleukin-6 (IL-6) GGG/GGG promoter (-597/-572/-174)genotype were shown to have a better long-term outcome. Further, the same (-597/-572/-174)genotype was found to be associated with less IL-6 production in healthy control subjects. To verify this observation in potential kidney transplant recipients, IL-6 production was analyzed in 85/142 hemodialysis patients. We could not confirm an impaired IL-6 secretion in carriers of the GGG/GGG (-597/-572/-174)genotype and propose a significantly lower IL-6 production in hemodialysis patients versus healthy control subjects to explain this. However, we suggest subsequent studies of IL-6 production in kidney allograft recipients to further elucidate the pathophysiological relevance of IL-6 for transplant outcome.

[1]  M. Pan,et al.  Interleukin-6 promoter polymorphisms and susceptibility to atrial fibrillation in elderly Han Chinese patients with essential hypertension. , 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  M. Arias,et al.  Influence of interleukin-6 promoter polymorphism -174 g/c on kidney graft outcome. , 2010, Transplantation proceedings.

[3]  N. Vaziri,et al.  Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  P. Bugert,et al.  Optimized PCR with sequence specific primers (PCR-SSP) for fast and efficient determination of Interleukin-6 Promoter -597/-572/-174Haplotypes , 2009, BMC Research Notes.

[5]  B. Banas,et al.  The impact of "high-producer" interleukin-6 haplotypes on cardiovascular morbidity and mortality in a kidney transplant population. , 2009, Transplantation proceedings.

[6]  P. Paré,et al.  Associations of IL6 polymorphisms with lung function decline and COPD , 2009, Thorax.

[7]  S. Kashima,et al.  Correlation between polymorphisms at interleukin‐6 but not at interleukin‐10 promoter and the risk of human T lymphotropic virus type I‐associated myelopathy/tropical spastic paraparesis in Brazilian individuals , 2008, Journal of medical virology.

[8]  C-J Chen,et al.  Analysis of polymorphisms in the promoter region and protein levels of interleukin-6 gene among gout patients. , 2008, Clinical and experimental rheumatology.

[9]  K. Ivens,et al.  Influence of cytokine genes polymorphisms on long‐term outcome in renal transplantation , 2007, Clinical transplantation.

[10]  C. Härtel,et al.  The impact of interleukin‐6 promoter −597/−572/−174genotype on interleukin‐6 production after lipopolysaccharide stimulation , 2006, Clinical and experimental immunology.

[11]  B. Jaber,et al.  Genetics in Dialysis: Gene Polymorphism Association Studies in Dialysis: Anemia and Host Immunity , 2006, Seminars in dialysis.

[12]  C. Härtel,et al.  Immunosuppressive Activity of the Immunophilin‐binding Drug Sanglifehrin A in Human Whole Blood: Potent Inhibition of Interleukin‐6 Produced by Lymphocytes and Monocytes , 2006, Scandinavian journal of immunology.

[13]  H. Kirchner,et al.  Cooperative Influence of the Interleukin‐6 Promoter Polymorphisms –597, –572 and –174 on Long‐Term Kidney Allograft Survival , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  G. Malaponte,et al.  IL‐1β, TNF‐α and IL‐6 release from monocytes in haemodialysis patients in relation to dialytic age , 2002 .

[15]  H. Kirchner,et al.  Production of monokines in patients under polysulphone haemodiafiltration is influenced by the ultrafiltration flow rate. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  S. Marshall,et al.  DONOR CYTOKINE GENOTYPE INFLUENCES THE DEVELOPMENT OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION , 2001, Transplantation.

[17]  F. Green,et al.  Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[18]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[19]  A. Ray,et al.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion , 1990, Molecular and cellular biology.